Tear Film Stability and Improvement of Asthenopia: Efficacy Observation of 0.05% Cyclosporine in Dry Eye Patients With Short BUT

Zhejiang University

Status: Completed

Conditions: Dry Eye Disease (DED); Asthenopia

Treatments: Drug: 0.05% cyclosporine eyedrops; Drug: 0.1% sodium hyaluronate eye drop

Study type: Interventional

Funder types: Other

Identifiers

NCT06981104

2024-0146

Details and patient eligibility

About

At present, research on cyclosporine mainly focuses on patients with moderate to severe dry eye. Based on the importance of the vicious cycle of inflammation in the pathogenesis of dry eye and the mechanism of cyclosporine, investigators believe that it may also have therapeutic effects in patients with mild to moderate dry eye, and may have certain advantages compared to traditional artificial tear therapy. In summary, this study intends to use a randomized, double-blind, parallel controlled trial to evaluate the therapeutic efficacy and safety of 0.05% cyclosporine eye drops in patients with mild to moderate dry eyes.

Enrollment: 60 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. 18-75 years old (including 18 and 75 years old), male or female;
2. Meets the diagnostic criteria for dry eye syndrome in China (2020) and is mild dry eye 1) Dry Eye Questionnaire (OSDI) score ≥ 13 points; 2) BUT ≤ 10 seconds or Schirmer I ≤ 5mm/5 minutes 3) Corneal staining positive ≤ 5 points.
3. At least one of OSDI, BUT, and Schirmer I meets the moderate standard OSDI ≥ 23 points; BUT<5 seconds; Schirmer I < 5mm/5min
4. The subjects themselves signed an informed consent form and voluntarily participated in this study.

Exclusion criteria

1. Women who are breastfeeding or pregnant, or men and women of childbearing age who are unable to use effective contraceptive methods during the study period;
2. Those who need to wear contact lenses during treatment;
3. Acute inflammation, infection, allergy, and trauma of the eyes;
4. There are obvious scars or keratinization on the eyelid margin;
5. Have undergone eye or eyelid surgery within the 6 months prior to enrollment;
6. Diagnosed with facial nerve paralysis or ocular nerve paralysis within 6 months prior to enrollment;
7. Currently using lacrimal duct embolization (permanent lacrimal plug or treatment with lacrimal plug within 6 months);
8. I am currently taking medication that may affect dry eye syndrome.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

60 participants in 2 patient groups, including a placebo group

0.05% cyclosporine froup(Group C)

Experimental group

Treatment:

Drug: 0.05% cyclosporine eyedrops

0.1% sodium hyaluronate group（Group S）

Placebo Comparator group

Treatment:

Drug: 0.1% sodium hyaluronate eye drop